Mission and Focus

LENZ Therapeutics is dedicated to improving vision for the millions of people who experience presbyopia. Presbyopia is a nearly universal condition that typically begins to affect individuals in their early to mid-40s, gradually reducing the eye's ability to focus on close objects. Traditional solutions have long included reading glasses, bifocals, progressive lenses, and contact lenses. LENZ aims to provide a pharmaceutical alternative—an eye drop treatment that can temporarily restore near vision without the need for corrective eyewear.

The company's approach centers on the concept of pharmacological correction of near vision through the modulation of pupil size. By using a miotic agent to constrict the pupil, the treatment leverages the "pinhole effect," which increases the depth of focus of the eye and thereby improves near visual acuity.

Lead Product Candidate

LNZ100 (aceclidine)

LNZ100 is the company's lead product candidate. It is a preservative-free eye drop formulation of aceclidine, a miotic agent designed to constrict the pupil and improve near vision in individuals with presbyopia. Aceclidine is a cholinergic agonist that acts on the muscles controlling pupil size.

A key differentiator that LENZ emphasizes for aceclidine is its mechanism of action, which is intended to produce pupil constriction while minimizing the impact on the eye's accommodative function and the ciliary muscle. This distinction is important because it aims to reduce side effects such as brow ache and myopic shift (a temporary worsening of distance vision) that can be associated with other miotic agents used to treat presbyopia.

LENZ has positioned LNZ100 as a once-daily treatment intended to deliver a rapid onset of improved near vision and a long duration of effect throughout the day. The goal is to provide patients with a convenient, effective option that works across a broad range of iris colors and pupil sizes.

LNZ101

In addition to LNZ100, the company has developed LNZ101, which is a combination formulation that pairs aceclidine with brimonidine. Brimonidine is an alpha-adrenergic agonist that has been used in eye care and may contribute additional pupil-modulating and vasoconstrictive effects. LNZ101 was studied as part of the company's clinical program to evaluate the potential benefits of the combination compared with aceclidine alone.

Clinical Development

LENZ Therapeutics has conducted a comprehensive clinical development program to evaluate the safety and efficacy of its presbyopia treatments. This program has included pivotal Phase 3 clinical trials designed to assess improvements in near visual acuity among presbyopic patients. The trials measured endpoints such as the proportion of patients achieving a clinically meaningful improvement in near vision without a loss of distance vision, along with the onset and duration of the treatment effect.

The company's Phase 3 studies were structured to support a New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA). Based on the outcomes of these studies, LENZ selected LNZ100 as its lead candidate for regulatory submission and commercialization efforts.

Regulatory Pathway

LENZ Therapeutics has pursued regulatory approval through the FDA for its lead presbyopia treatment. The company's regulatory strategy is centered on demonstrating that its aceclidine-based eye drop provides a favorable balance of efficacy, safety, and convenience for the large and growing population of adults affected by presbyopia. Achieving FDA approval is a critical step toward the company's goal of bringing its product to market and making it available to eye care professionals and their patients.

Market Opportunity

Presbyopia represents a significant and expanding market opportunity. As a condition that affects the vast majority of adults over the age of 45, the potential patient population numbers in the many tens of millions in the United States alone, with a substantially larger global population. Many of these individuals seek alternatives to reading glasses and other corrective eyewear, particularly options that offer convenience and preserve a more youthful and natural appearance.

LENZ Therapeutics aims to capture a share of this large market by offering a pharmaceutical eye drop that can be prescribed by eye care professionals, including optometrists and ophthalmologists. The company views the professional eye care channel as an important avenue for reaching patients and building awareness of pharmaceutical presbyopia treatment as a viable option.

Products and Services Summary

LENZ Therapeutics is fundamentally a drug development and commercialization company. Its offerings are centered on the following:

• LNZ100 (aceclidine): A once-daily, preservative-free eye drop for the treatment of presbyopia, designed to improve near vision through pupil modulation while minimizing common miotic side effects. This is the company's lead product candidate.

• LNZ101 (aceclidine plus brimonidine): A combination eye drop formulation developed and studied as part of the company's presbyopia program.

The company does not offer a broad portfolio of consumer products or services in the traditional sense; rather, its value lies in its clinical-stage and commercial-stage pharmaceutical assets focused specifically on eye care and vision correction.

Leadership and Corporate Profile

LENZ Therapeutics is led by an experienced management team with backgrounds in biopharmaceutical development, eye care, and commercialization. The company has assembled expertise across clinical development, regulatory affairs, and commercial operations to support the advancement and eventual launch of its presbyopia treatment.

As a publicly traded company, LENZ Therapeutics is subject to the reporting requirements of the U.S. Securities and Exchange Commission and provides regular updates to investors regarding its clinical progress, regulatory milestones, and financial position. The company is based in Del Mar, California, situated within a region that is home to a strong life sciences and biotechnology ecosystem.

Conclusion

LENZ Therapeutics is a specialized biopharmaceutical company with a clear and focused mission: to transform the treatment of presbyopia through an innovative pharmaceutical eye drop. By advancing its aceclidine-based candidates through rigorous clinical development and toward regulatory approval, the company seeks to offer a compelling alternative to traditional corrective eyewear for the enormous population of adults affected by age-related loss of near vision. Its emphasis on a differentiated mechanism of action, once-daily convenience, and efficacy across diverse patient characteristics reflects its commitment to addressing a widespread and enduring vision care need.